Vivos Therapeutics, INC Form 4 insider transactions

Michael C Skaff, a 10% owner of Vivos Therapeutics, Inc., purchased 5,498,660 shares of common stock on June 30, 2026 for $0.58 per share.

Michael C. Skaff, a Director at Vivos Therapeutics, Inc., reported transactions involving the conversion of a promissory note and the acquisition of warrants, increasing his indirect beneficial ownership.

Vivos Therapeutics CEO Ronald Kirk Huntsman acquired 315,421 stock options and disposed of 3,461 common shares, while also holding 69,600 shares indirectly.

Vivos Therapeutics' Chief Financial Officer, Bradford K. Amman, acquired 149,533 stock options after shareholder approval of the 2024 Omnibus Equity Incentive Plan.

Ronald Kirk Huntsman, CEO of Vivos Therapeutics, reports the acquisition of 20,000 stock options and a disposition of 3,461 shares of common stock.

Director Leonard J. Sokolow of Vivos Therapeutics, Inc. received a grant of 4,000 stock options on June 20, 2024.

Director Matthew Thompson reports acquisition of 4,000 stock options in Vivos Therapeutics, Inc.

Director Ralph Elias Green received a grant of 4,000 stock options from Vivos Therapeutics, Inc. on June 20, 2024.

Director Anja B. Krammer acquired 4,000 stock options in Vivos Therapeutics, Inc. on June 20, 2024.

Bradford K. Amman, CFO of Vivos Therapeutics, Inc., reports the acquisition of 15,000 stock options on June 20, 2024.

Director Mark F. Lindsay of Vivos Therapeutics, Inc. acquired 4,000 stock options on June 20, 2024, as reported in a Form 4 filing with the SEC.